The American Oncology Network is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
The American Oncology Network (AON) is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.
The founders of AON expected a high level of success because of the organizations roots in Florida Cancer Specialists & Research Institute (FCS). AONs sister organization, FCS was established in 1984 and is thriving in the state of Florida. Today, it has more than 100 locations and is recognized as the largest privately held hematology/oncology practice in the United States. AONs management team was carried over from FCS.
As members of AON, oncology practices have access to resources like administration, management, billing, information technology, accounting, and other shared services that make it easier for oncologists to focus on caring for patients. Additionally, the central lab, central pathology, clinical research, and specialty pharmacy programs that AON provides help smaller oncology practices prevent from having to transfer their patients outside of the community treatment environment. The way AON operates varies from state to state, based on regulations and compliance. However, all member practices, large and small, can experience the benefits of the network.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More